Acinetobacter Infections - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 119 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections - Pipeline Review, H1 2017, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape.

Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene and recent surgery or procedure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acinetobacter Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acinetobacter Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acinetobacter Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 3, 28 and 16 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 8 molecules, respectively.

Acinetobacter Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acinetobacter Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Acinetobacter Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acinetobacter Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acinetobacter Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acinetobacter Infections (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acinetobacter Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acinetobacter Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Acinetobacter Infections - Overview 7
Acinetobacter Infections - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
Acinetobacter Infections - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Acinetobacter Infections - Companies Involved in Therapeutics Development 25
Achaogen Inc 25
Adenium Biotech ApS 25
Aridis Pharmaceuticals LLC 26
Atterx Biotherapeutics Inc 26
AvidBiotics Corp 27
Emergent BioSolutions Inc 27
Entasis Therapeutics Inc 28
Evaxion Biotech ApS 28
F. Hoffmann-La Roche Ltd 29
FOB Synthesis Inc 29
Hsiri Therapeutics LLC 30
LegoChem Biosciences Inc 30
Melinta Therapeutics Inc 31
Nosopharm SAS 31
Novabiotics Ltd 32
Omnia Molecular Ltd 32
Peptilogics Inc 33
Pfizer Inc 33
Redx Pharma Plc 34
Sarepta Therapeutics Inc 34
Sealife PHARMA GMBH 35
Shionogi & Co Ltd 35
Techulon Inc 36
Tetraphase Pharmaceuticals Inc 36
Vaxdyn SL 37
Xellia Pharmaceuticals ApS 37
Acinetobacter Infections - Drug Profiles 38
A-3APO - Drug Profile 38
AA-139 - Drug Profile 40
AB-877 - Drug Profile 41
Acinetobacter vaccine - Drug Profile 42
Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile 43
Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile 44
AR-401 - Drug Profile 45
AvR2-V10 - Drug Profile 46
CA-824 - Drug Profile 48
cefiderocol - Drug Profile 49
CSA-13 - Drug Profile 52
EBX-004 - Drug Profile 54
ETX-2514 + sulbactam sodium - Drug Profile 55
EV-035 - Drug Profile 57
FAB-001 - Drug Profile 59
FSI-1671 - Drug Profile 60
FSI-1686 - Drug Profile 61
G-3KL - Drug Profile 62
GN-4474 - Drug Profile 63
HT-06 - Drug Profile 64
HT-07 - Drug Profile 65
HT-10 - Drug Profile 66
JSM-11 - Drug Profile 67
LCB-100200 - Drug Profile 68
MDN-0057 - Drug Profile 69
Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile 71
NOSO-95179 - Drug Profile 72
NP-432 - Drug Profile 73
Peptides for Infectious Diseases - Drug Profile 74
pneumonia vaccine - Drug Profile 75
RX-05 - Drug Profile 76
RXP-873 - Drug Profile 77
SLP-0901 - Drug Profile 78
SLP-0905 - Drug Profile 79
Small Molecule for Acinetobacter baumannii Infections - Drug Profile 80
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 81
Small Molecule to Target Bacterial Cell Membrane for Acinetobacter Infections - Drug Profile 82
Small Molecules for Acinetobacter baumannii Infection - Drug Profile 83
Small Molecules for Bacterial and Fungal Infections - Drug Profile 84
Small Molecules for Bacterial Infections - Drug Profile 85
Small Molecules for Bacterial Infections - Drug Profile 86
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 87
Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections - Drug Profile 88
Small Molecules to Inhibit DNA Gyrase Subunit A and Topoisomerase IV for Gram-Negative Bacterial Infections - Drug Profile 89
Small Molecules to Inhibit LpxC for Gram Negative Bacterial Infections - Drug Profile 90
Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections and Respiratory Diseases - Drug Profile 91
Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections - Drug Profile 92
SPR-741 - Drug Profile 93
Synthetic Peptide to Target Bacterial Cell Membrane for Gram Negative and Gram Positive Bacterial Infections - Drug Profile 96
Synthetic Peptides for Infectious Disease - Drug Profile 97
TN-5 - Drug Profile 98
TP-6076 - Drug Profile 99
VNRX-5113 - Drug Profile 100
VXD-001 - Drug Profile 101
VXD-003 - Drug Profile 102
XEL-1001 - Drug Profile 103
XEL-1002 - Drug Profile 104
XEL-1003 - Drug Profile 105
XEL-1007 - Drug Profile 106
Acinetobacter Infections - Dormant Projects 107
Acinetobacter Infections - Product Development Milestones 109
Featured News & Press Releases 109
Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 114
Disclaimer 115

List of Tables

Number of Products under Development for Acinetobacter Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Acinetobacter Infections - Pipeline by Achaogen Inc, H1 2017
Acinetobacter Infections - Pipeline by Adenium Biotech ApS, H1 2017
Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
Acinetobacter Infections - Pipeline by Atterx Biotherapeutics Inc, H1 2017
Acinetobacter Infections - Pipeline by AvidBiotics Corp, H1 2017
Acinetobacter Infections - Pipeline by Emergent BioSolutions Inc, H1 2017
Acinetobacter Infections - Pipeline by Entasis Therapeutics Inc, H1 2017
Acinetobacter Infections - Pipeline by Evaxion Biotech ApS, H1 2017
Acinetobacter Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Acinetobacter Infections - Pipeline by FOB Synthesis Inc, H1 2017
Acinetobacter Infections - Pipeline by Hsiri Therapeutics LLC, H1 2017
Acinetobacter Infections - Pipeline by LegoChem Biosciences Inc, H1 2017
Acinetobacter Infections - Pipeline by Melinta Therapeutics Inc, H1 2017
Acinetobacter Infections - Pipeline by Nosopharm SAS, H1 2017
Acinetobacter Infections - Pipeline by Novabiotics Ltd, H1 2017
Acinetobacter Infections - Pipeline by Omnia Molecular Ltd, H1 2017
Acinetobacter Infections - Pipeline by Peptilogics Inc, H1 2017
Acinetobacter Infections - Pipeline by Pfizer Inc, H1 2017
Acinetobacter Infections - Pipeline by Redx Pharma Plc, H1 2017
Acinetobacter Infections - Pipeline by Sarepta Therapeutics Inc, H1 2017
Acinetobacter Infections - Pipeline by Sealife PHARMA GMBH, H1 2017
Acinetobacter Infections - Pipeline by Shionogi & Co Ltd, H1 2017
Acinetobacter Infections - Pipeline by Techulon Inc, H1 2017
Acinetobacter Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
Acinetobacter Infections - Pipeline by Vaxdyn SL, H1 2017
Acinetobacter Infections - Pipeline by Xellia Pharmaceuticals ApS, H1 2017
Acinetobacter Infections - Dormant Projects, H1 2017
Acinetobacter Infections - Dormant Projects, H1 2017 (Contd..1), H1 2017